Feb 26, 2026 07:00AM
Feb 23, 2026 07:00AM
Feb 23, 2026 07:00AM
Jan 14, 2026 07:00AM
Jan 14, 2026 07:00AM
Nov 6, 2025 07:00AM
Sep 20, 2025 11:00AM C4 Therapeutics reports phase 1 multiple myeloma trial results
Sep 20, 2025 11:00AM
Sep 17, 2025 04:33AM
Sep 4, 2025 07:00AM
Aug 7, 2025 07:00AM
May 7, 2025 07:00AM
Nov 5, 2024 07:05AM
Oct 15, 2024 04:03PM C4 Therapeutics Inc. (CCCC) Appoints Paige Mahaney as Chief Scientific Officer, Stewart Fisher Retires
Oct 15, 2024 04:01PM
Sep 13, 2024 10:00AM
Sep 13, 2024 10:00AM
Aug 8, 2023 07:00AM
Jul 5, 2023 07:01AM
Jul 5, 2023 07:00AM
Jun 20, 2023 07:03AM C4 Therapeutics Inc. (CCCC) Appoints Leonard Reyno as Chief Medical Officer
Jun 20, 2023 07:00AM
May 30, 2023 07:10AM
May 30, 2023 07:00AM
Nov 3, 2022 07:00AM
Nov 3, 2022 07:00AM
Sep 29, 2022 07:01AM
Sep 29, 2022 07:00AM C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
Sep 29, 2022 07:00AM
May 16, 2022 08:00AM
May 16, 2022 08:00AM
May 5, 2022 08:00AM
May 5, 2022 08:00AM
Mar 9, 2022 08:00AM
Mar 9, 2022 08:00AM C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
Mar 9, 2022 08:00AM
Feb 24, 2022 07:00AM
Feb 24, 2022 07:00AM
Jan 10, 2022 07:03AM
Jan 10, 2022 07:00AM
Jan 10, 2022 07:00AM
Nov 10, 2021 04:01PM C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
Nov 10, 2021 04:01PM
Aug 11, 2021 04:02PM
Aug 11, 2021 04:02PM
Aug 11, 2021 04:01PM
Aug 11, 2021 04:01PM
Jun 14, 2021 08:00AM
Jun 14, 2021 08:00AM C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies
May 13, 2021 04:01PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All